Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Heart Failure

• Publication date

  2015-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1002/ejhf.286PMID 26139583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.

  2013cited by this paper
• Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

  2013cited by this paper
• Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).

  2013cited by this paper
• NT-proB natriuretic peptide, risk factors and asymptomatic left ventricular dysfunction: results of the SCReening Evaluation of the Evolution of New Heart Failure study (SCREEN-HF).

  2013cited by this paper
• Preventing cardiovascular disease in primary care: role of a national risk factor management program.

  2012cited by this paper
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)

  2012cited by this paper
• Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.

  2012cited by this paper
• Multiple risk factor interventions for primary prevention of coronary heart disease.

  2011cited by this paper
• Appropriate perspectives for health care decisions.

  2010cited by this paper
• Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation

  2010cited by this paper
• Screening for cardiovascular risk in asymptomatic patients.

  2010cited by this paper
• C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

  2010cited by this paper
• Improving lifestyle and risk perception through patient involvement in nurse-led cardiovascular risk management: a cluster-randomized controlled trial in primary care.

  2010cited by this paper
• Nichtmedikamentöse Sekundärprävention der koronaren Herzkrankheit (KHK)

  2009cited by this paper
• Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

  2009cited by this paper
• European Guidelines on Cardiovascular Disease Prevention

  2009cited by this paper
• European cardiovascular disease statistics

  2008cited by this paper
• Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study

  2006cited by this paper
• Elevated BNP with normal systolic function in asymptomatic individuals at-risk for heart failure: a marker of diastolic dysfunction and clinical risk

  2006cited by this paper
• Estimating the value of information in strategies for identifying patients at high risk of cardiovascular disease.

  2006cited by this paper
• Barriers to implementing cardiovascular risk tables in routine general practice

  2004cited by this paper
• Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population.

  2003cited by this paper
• Medical economics and the assessment of value in cardiovascular medicine: Part I.

  2002cited by this paper
• Exercise‐based Rehabilitation for Coronary Heart Disease

  2001cited by this paper
• Multiple risk factor interventions for primary prevention of coronary heart disease.

  2000cited by this paper
• A cost effective, community based heart health promotion project in England: prospective comparative study

  1997cited by this paper
• Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

  1994cited by this paper

• Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association.

  2026cites this paper
• Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes

  2025cites this paper
• Diabetic cardiomyopathy: merely a complication or a distinct understudied disease?

  2025cites this paper
• Prioritising the primary prevention of heart failure.

  2025cites this paper
• Biomarker-based pre-heart failure screening in a middle-aged rural population.

  2025cites this paper
• Heart failure in China: a macroeconomic modelling study of intervention strategies.

  2025cites this paper
• Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.

  2025cites this paper
• Machine learning‐based prediction of elevated N terminal pro brain natriuretic peptide among US general population

  2024cites this paper
• An update on utilising brain natriuretic peptide for risk stratification, monitoring and guiding therapy in heart failure

  2023cites this paper
• A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

  2023influential citation
• Prediction models for heart failure in the community: A systematic review and meta‐analysis

  2023cites this paper
• NT‐proBNP and All‐Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study

  2023cites this paper
• Natriuretic Peptide Screening for Primary Prevention or Early Detection of Heart Failure: A Pharmacist-Driven Team-Based Approach.

  2022cites this paper
• B-type natriuretic peptide as prognostic marker in primary care patients with and without heart failure

  2022cites this paper
• Elevated NT-proBNP as a cardiovascular disease risk equivalent: Evidence from the Atherosclerosis Risk in Communities (ARIC) Study.

  2022cites this paper
• Impact of 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations for the Evaluation of Left Ventricular Diastolic Function on Predicting Outcomes in Patients with Diabetes and Hypertension without a History of Cardiovascular Disease

  2022cites this paper
• Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe

  2022cites this paper
• LVS‐HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World‐Wide Registry

  2021cites this paper
• Heart failure risk estimation based on novel biomarkers

  2021cites this paper
• Multiplexed measurement of candidate blood protein biomarkers of heart failure

  2021cites this paper
• Biomarkers in Heart Failure: Clinical Insights.

  2021cites this paper
• Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia

  2021cites this paper
• Point-of-care testing of (N-terminal pro) B-type natriuretic peptide for heart disease patients in home care and ambulatory care settings

  2020cites this paper
• New‐onset heart failure in the STOP‐HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure

  2020cites this paper
• Biomarkers for coronary artery disease and heart failure

  2020cites this paper
• Diagnostic accuracy and clinical impact of natriuretic peptide screening for the detection of heart failure in the community: a protocol for systematic review and meta-analysis

  2019cites this paper
• Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues.

  2019cites this paper
• Developing a disease management program for the improvement of heart failure outcomes: the do’s and the don’ts

  2019cites this paper
• Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

  2019cites this paper
• Comparing the influence of 2009 versus 2016 ASE/EACVI diastolic function guidelines on the prevalence and echocardiographic characteristics of preclinical diastolic dysfunction (stage B heart failure) in a Hispanic population with type 2 diabetes mellitus.

  2019cites this paper
• Evaluation of Serum Levels of Inflammation, Fibrinolysis and Oxidative Stress Markers in Coronary Artery Disease Prediction: A Cross-Sectional Study

  2019cites this paper
• World Heart Federation Roadmap for Heart Failure.

  2019cites this paper
• Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019

  2019cites this paper
• Reducing Heart Failure Risk In People With Diabetes - the STOP HF Midlands Project.

  2019cites this paper
• Heart failure : role of metabolic biomarkers, ejection fraction, and sex

  2018cites this paper
• Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

  2018cites this paper
• Predicting heart failure: one size does not fit all

  2018cites this paper
• Natriuretic Peptides in Chronic Heart Failure

  2018cites this paper
• [Expert consensus on the usefulness of natriuretic peptides in heart failure.]

  2018cites this paper
• High-Sensitive Cardiac Troponin for Prediction of Clinical Heart Failure: Are We Ready for Prime Time?

  2017cites this paper
• Evolving Use of Natriuretic Peptides as Part of Strategies for Heart Failure Prevention.

  2017cites this paper
• Natriuretic Peptide-based Screening and Prevention of Heart Failure.

  2017cites this paper
• Heart failure 2016: still more questions than answers.

  2017cites this paper
• Natriuretic peptides and integrated risk assessment for cardiovascular disease : an individual-participant-data meta-analysis Natriuretic Peptides

  2016cites this paper
• Echo and natriuretic peptide guided therapy improves outcome and reduces worsening renal function in systolic heart failure: An observational study of 1137 outpatients.

  2016cites this paper
• Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

  2016cites this paper
• Biomarkers to identify and prevent new‐onset heart failure in the community

  2016cites this paper
• Natriuretic peptide levels taken following unplanned admission to a cardiology department predict the duration of hospitalization

  2016cites this paper
• How peptide technology has improved costs and outcomes in patients with heart failure

  2016cites this paper
• Natriuretic peptides revisited: new potentials and challenges in heart failure.

  2016cites this paper
• Biomarker‐based risk prediction in the community

  2016cites this paper
• The healthcare costs of heart failure during the last five years of life: A retrospective cohort study

  2016cites this paper
• Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes

  2016cites this paper
• Innovation in heart failure: early diagnosis in community settings

  year unknowncites this paper